Vishal Doshi founded and leads the growth of AUM Biosciences, an award-winning company that is challenging the status quo, and is ready to enable significant disruptions within the existing pharma and biotech landscape by enabling the development of precision therapies for the Asia-Pacific region. He also serves on AUM’s board of directors.
Under Vishal’s leadership, AUM has become a clinical-stage company and has developed a portfolio of transformative cancer medicines within 12 months of inception. Within the first year of operations, AUM was awarded the 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year by Frost and Sullivan. Vishal currently serves as a KOL with the Korean Health Industry Development Initiative (KHIDI).
He has extensive experience in structuring and managing risk-sharing deals in various roles worth over USD 1 billion in drug development in the pharmaceutical and CRO industry, across the US, Europe and Asia. During a career that has spanned across various sectors, Vishal has passionately championed the potential benefits of precision medicine and healthcare reform for patients. AUM’s vision is central to his belief in developing affordable and accessible cancer treatment options.
Vishal received a B.Pharm from the University of Mumbai. He has extensive research experience in Aromatase inhibitors for the treatment of Breast Cancer. Vishal also holds a Master’s Degree in Pharmaceutical Sciences from Kingston University, UK.